Publish in this journal
Journal Information
Vol. 52. Issue 10.
Pages 541 (October 2016)
Vol. 52. Issue 10.
Pages 541 (October 2016)
Letter to the Editor
DOI: 10.1016/j.arbr.2016.07.026
Full text access
Eosinophils and Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Eosinófilos y corticoides inhalados en la enfermedad pulmonar obstructiva crónica
Adolfo Baloira Villara,
Corresponding author

Corresponding author.
, Abel Pallarés Sanmartína, Marta Núñez Fernándezb
a Servicio de Neumología, Complejo Hospitalario Universitario de Pontevedra, Casas Novas, Pontevedra, Spain
b Servicio de Neumología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain
Article information
Full Text
Download PDF
Full Text
To the Editor:

We welcome and largely agree with the comments on our recent article.1 Further insight is needed into the role played by blood eosinophilia in the management of chronic obstructive pulmonary disease (COPD). Perhaps the most important aspect to clarify is the absolute or relative number of eosinophils needed for either prognostic or therapeutic purposes, or even to define a potential new COPD phenotype. As the authors point out, most of the studies conducted to date consist of post hoc analyses; however, all report the same results, namely, significant response to inhaled corticosteroids is only achieved with certain blood eosinophil levels. We wrote our scientific letter over 1 year ago, and since then new studies have contributed further evidence in support of this finding. A re-analysis of the results of the ISOLDE study showed the FEV1 decline was reduced by around 34mL/year in patients with eosinophil count ≥2% at the start of the study, while no difference in decline was observed with <2%.2 Another approach to this issue was taken in the post hoc analysis of the WISDOM trial, where exacerbations were observed to increase after withdrawal of fluticasone in patients with eosinophil counts of ≥2%, with a relative risk (RR) of 1.22. The increase in the exacerbation rate became more pronounced as the eosinophil cutoff level rose (≥ 4%, RR: 1.63; ≥5%, RR: 1.82).3

In conclusion, although we agree with most of the authors’ comments, we believe that evidence has shown blood eosinophil levels to be an excellent biomarker of response to inhaled corticosteroids in COPD, and could even constitute a specific COPD phenotype.4

R. Golpe, I. Martín-Robles, P. Sanjuán-López.
Corticoides inhalados, eosinófilos y exacerbaciones de enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 52 (2016), pp. 229
N.C. Barnes, R. Sharma, S. Lettis, P.M. Calverley.
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
Eur Respir J, 47 (2016), pp. 1374-1382
H. Watz, K. Tetzlaff, E.F. Wouters, A. Kirsten, H. Magnussen, R. Rodríguez-Roisin, et al.
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
A. Baloira Villar, A. Pallarés Sanmartín.
Enfermedad pulmonar obstructiva crónica con eosinofilia, ¿un fenotipo emergente?.
Arch Bronconeumol, 52 (2016), pp. 177-178

Please cite this article as: Villar AB, Sanmartín AP, Fernández MN. Eosinófilos y corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2016;52:541.

Copyright © 2016. SEPAR
Archivos de Bronconeumología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.